ELAN
Elanco Animal Health Incorporated
ELAN's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ELAN overall, supported by stronger fundamentals and stronger modeled upside.
ELAN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Weak |
ELAN's revenue and cash flow are currently healthy, but its profitability and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ELAN PE Valuation
ELAN has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ELAN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for ELAN, with profitability improving. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ELAN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.24 | — |
| Q3 2026 | -$0.29 | -514% |
| Q2 2026 | -$0.40 | -146% |
| Q1 2026 | -$0.49 | -165% |
| Q4 2025 | -$0.47 | -169% |
| Q3 2025 | $0.07 | -83% |
| Q2 2025 | $0.87 | +$3.42 |
| Q1 2025 | $0.75 | +$3.40 |
| Q4 2024 | $0.68 | +$3.18 |
ELAN has swung to a loss: it lost $0.29 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ELAN on earnings quality, reporting a profit while its opponent remains loss making.
ELAN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.3B | +11% |
| Q2 2026 | $1.4B | +10% |
| Q1 2026 | $1.4B | +15% |
| Q4 2025 | $1.1B | +12% |
| Q3 2025 | $1.1B | +10% |
| Q2 2025 | $1.2B | +4.8% |
| Q1 2025 | $1.2B | -1% |
| Q4 2024 | $1B | -1.4% |
ELAN's revenue has grown year over year for six quarters in a row: $1.3B last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.9% | +6.3 points |
| Q2 2026 | 4.1% | +2.1 points |
| Q1 2026 | 6.3% | +1.3 points |
| Q4 2025 | -23% | -18 points |
| Q3 2025 | -4.4% | -59 points |
| Q2 2025 | 2% | +4.7 points |
| Q1 2025 | 5% | +4 points |
| Q4 2024 | -5% | +7.3 points |
ELAN's operating margin was 1.9% last quarter, up 6.3 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ELAN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ELAN on profitability, with a higher operating margin.
ELAN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $156M | +23% |
| Q2 2026 | $244M | +36% |
| Q1 2026 | -$38M | +$31M |
| Q4 2025 | $46M | -65% |
| Q3 2025 | $127M | +5.8% |
| Q2 2025 | $180M | +8.4% |
| Q1 2025 | -$69M | -$47M |
| Q3 2024 | $120M | -39% |
ELAN generated $408M in free cash flow over the past year, up 11% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ELAN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +600K shares |
| 1 year | +2% | +9.7M shares |
| 3 years | +2.8% | +13.8M shares |
| 5 years | +3.9% | +19.2M shares |
| Available history | +37% | +136M shares |
ELAN has 507M diluted shares, up 2% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ELAN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ELAN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.4x | High |
| Q2 2026 | 6.4x | High |
| Q1 2026 | 7.2x | High |
| Q4 2025 | 7.6x | High |
| Q3 2025 | 5.4x | High |
| Q2 2025 | 2.9x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | 3.4x | Elevated |
ELAN's net debt is about 5.4 years of its operating earnings (EBITDA), about the same as a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over ELAN on leverage, with a lower net debt burden relative to earnings.
ELAN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.4 | Neutral |
| Stochastic | 59.7 | Neutral |
ELAN's weekly RSI is 61 (neutral) and its Stochastic is 60 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ELAN PE vs Healthcare Sector
| Metric | ELAN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ELAN has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ELAN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.6 | 12% above |
| 20 week MA | $24.0 | 11% above |
| 50 week MA | $23.7 | 12% above |
| 100 week MA | $19.2 | 38% above |
| 200 week MA | $16.0 | 65% above |
ELAN is in an uptrend: it's above all five of its weekly moving averages, and 65% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
ELAN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.3 | $30.5 | +4.1% |
| 2021 | $30.5 | $28.9 | -5.4% |
| 2022 | $28.9 | $11.7 | -59% |
| 2023 | $11.7 | $14.9 | +27% |
| 2024 | $14.9 | $12.1 | -19% |
| 2025 | $12.1 | $22.6 | +87% |
| 2026 YTD | $22.6 | $26.5 | +17% |
ELAN has finished lower in three of the last six years. It's up 17% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ELAN on returns for 2026, with the stronger performance.